News - Johnson & Johnson

Filter

Current filters:

Johnson & Johnson

Popular Filters

280 to 301 of 301 results

Opportunity in hepatitis C market for recently-approved Victrelis and Incivek; report

15-06-2011

Results from an on-line survey fielded just prior to the US Food and Drug Administration approval of…

Anti-viralsIncivekJohnson & JohnsonMarkets & MarketingMerck & CoPharmaceuticalVertexVictrelis

Synthes and Eli Lilly to collaborate on osteoporosis treatments, including Forteo

13-06-2011

Swiss medical device firm Synthes (SIX: SYST.VX) and US drug major Eli Lilly (NYSE: LLY) have signed…

Anti-Arthritics/RheumaticsEli LillyForsteoForteoJohnson & JohnsonMarkets & MarketingPharmaceuticalResearchSynthes

PATH MVI partners with GSK and Crucell to develop second-generation vaccine against malaria

08-06-2011

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with…

CrucellGlaxoSmithKlineJohnson & JohnsonPharmaceuticalResearchTropical diseasesVaccines

Pharma majors slash vaccine prices to poorest countries

07-06-2011

Several pharmaceutical majors, including the UK’s GlaxoSmithKline (LSE: GSK), US giants Merck &…

GardasilGlaxoSmithKlineGlobalJohnson & JohnsonMerck & CoPharmaceuticalPricingRotarixSanofiSanofi PasteurVaccines

Johnson & Johnson faces $327 million penalty over Risperdal marketing

06-06-2011

Civil penalties amounting to just over $327 million have been announced in the case of State of South…

Johnson & JohnsonLegalNeurologicalNorth AmericaOrtho-McNeil-JanssenPharmaceuticalRisperdal

AVEO Pharma licenses RON-targeted antibodies to Johnson & Johnson unit for up to $555 million

01-06-2011

In a second significant deal this year, US cancer drug developer AVEO Pharmaceuticals (Nasdaq: AVEO)…

AVEO PharmaceuticalsCentocor Ortho BiotechJohnson & JohnsonLicensingOncologyPharmaceutical

Johnson & Johnson highlights R&D pipeline with plans to file for 11 drug approvals by 2015; GAVI seat for Crucell

27-05-2011

US health care major Johnson & Johnson (NYSE: JNJ) yesterday reviewed its growth strategies for its Pharmaceuticals…

Antibiotics and Infectious diseasesCardio-vascularImmunologicalsJohnson & JohnsonOncologyPharmaceuticalResearchVaccines

US Presidential visit to UK underlines cooperation in science, innovation and higher education

26-05-2011

The joint statement agreed yesterday by UK Prime Minister David Cameron and US President Barack Obama,…

EuropeJohnson & JohnsonNorth AmericaPharmaceuticalResearch

J&J Cilag unit buys Russian OTC brands from J B Chemicals for $260 million

25-05-2011

US health care giant Johnson & Johnson’ (NYSE: JNJ) Switzerland-based Cilag GmbH International has…

Cilag GmbHEuropeJ B Chemicals & PharmaceuticalsJohnson & JohnsonMergers & AcquisitionsPharmaceutical

US FDA approves Johnson & Johnson’s novel AIDS drug Edurant; expands use of Pfizer’s Sutent

23-05-2011

The US Food and Drug Administration on Friday approved US health care giant Johnson & Johnson’s…

Anti-viralsEdurantJohnson & JohnsonNorth AmericaOncologyPfizerPharmaceuticalRegulationrilpivirineSutentTibotec

Bayer/Ortho-McNeil’s VTE drug Xarelto will earn peak-year sales of $500 million to $1 billion

17-05-2011

Following its expected launch in the USA in 2012 for venous thromboembolism (VTE) prophylaxis in medically…

BayerCardio-vascularEliquisJohnson & JohnsonMarkets & MarketingOrtho-McNeilPharmaceuticalXarelto

Johnson & Johnson unit recalls batches of “smelly” AIDS drug Prezista

12-05-2011

Janssen-Cilag International, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), which…

Anti-viralsJanssen-CilagJohnson & JohnsonPharmaceuticalPrezistaRegulation

Highlights from Digestive Disease Week

11-05-2011

The 2011 Digestive Disease Week meeting in Chicago, USA, heard a number of interesting presentations…

Abbott LaboratoriesDificidGastro-intestinalsJohnson & JohnsonLubiprostoneOptimer PharmaceuticalsPharmaceuticalRemicadeResearchResolorShireStelara InjectionSucampo

Impax Labs sued again by J&J unit Alza over generic Concerta

09-05-2011

USA-based Impax Laboratories (Nasdaq: IPXL) confirmed on Friday that Alza Corp, a division of health…

ALZA CorpConcertaGenericsImpax LaboratoriesJohnson & JohnsonLegalNeurologicalNorth AmericaPatentsPharmaceuticalTeva Pharmaceutical Industries

Johnson & Johnson unit voluntarily withdraws NDA for trabectedin

03-05-2011

Centocor Ortho Biotech Products, a division of US health care giant Johnson & Johnson (NYSE: JNJ), says…

Centocor Ortho BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRegulationtrabectedinYondelisZeltia

Johnson & Johnson to buy orthopedic device maker Synthes for $21.3 billion

27-04-2011

Following earlier speculation, this morning, US diversified health care giant Johnson & Johnson (NYSE:…

Johnson & JohnsonMergers & AcquisitionsPharmaceuticalSynthes

280 to 301 of 301 results

Company Spotlight

Fibrotech

Fibrotech

Back to top